Holen Sie sich die Stockscreener-App
10.10
5.25%
-0.56
Handel nachbörslich:
10.09
-0.010
-0.10%
Schlusskurs vom Vortag:
$10.66
Offen:
$10.59
24-Stunden-Volumen:
315.27K
Relative Volume:
1.12
Marktkapitalisierung:
$200.25M
Einnahmen:
$33.18M
Nettoeinkommen (Verlust:
$-85.15M
KGV:
-3.3606
EPS:
-3.0054
Netto-Cashflow:
$-58.25M
1W Leistung:
-9.42%
1M Leistung:
-4.45%
6M Leistung:
-39.08%
1J Leistung:
-29.96%
1-Tages-Spanne:
$10.02
$10.59
1-Wochen-Bereich:
$10.02
$11.43
52-Wochen-Spanne:
$9.69
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
10.10 | 222.06M | 33.18M | -85.15M | -58.25M | -3.0054 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity? - Yahoo Finance
Understanding Momentum Shifts in (KROS) - Stock Traders Daily
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP - marketbeat.com
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.83, Implies 86% Upside - TradingView
BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 - marketscreener.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - marketbeat.com
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen - marketbeat.com
Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS - marketbeat.com
Keros Therapeutics, Inc. (KROS) Stock Analysis: Unveiling a 90.92% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - qz.com
FY2026 EPS Estimate for Keros Therapeutics Raised by Analyst - MarketBeat
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus - The Globe and Mail
KROS Maintained by Wells Fargo -- Price Target Lowered to $18.00 - GuruFocus
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners - marketbeat.com
Keros Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
KEROS THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $23 FROM $30 - Bitget
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS - marketbeat.com
Keros Therapeutics 2026: Revenue $0 EPS ($1.45) — 10-Q Summary - TradingView
Keros Therapeutics posts $28.7 million second quarter net loss - quiverquant.com
KROS: Reduced net loss and strong cash position support ongoing clinical progress into 2028 - TradingView
Keros Therapeutics Reports Second Quarter 2026 Financial Results - GlobeNewswire
Avoiding Lag: Real-Time Signals in (KROS) Movement - Stock Traders Daily
Keros Therapeutics Q2 net loss narrows on lower expenses - TradingView
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - qz.com
Keros Therapeutics, Inc. (KROS) Stock Analysis: Navigating a 113.63% Potential Upside in Biotechnology - DirectorsTalk Interviews
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
Keros Therapeutics to Receive $20M Development Milestone Payment From Takeda - Moomoo
Keros Therapeutics Earns Milestone Payment for Elritercept Trial - TipRanks
Keros Therapeutics to Receive $20M Milestone After First ELRiSE MDS Patient Dosed - TradingView
Keros Therapeutics (KROS) Holds Near Support After Modest GainLinear Regression - dars.gov.et
New Strong Sell Stocks for July 30th - theglobeandmail.com
Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday - marketbeat.com
Keros Therapeutics Inc (KROS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Keros Therapeutics Inc (KROS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Keros Therapeutics Inc (KROS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Keros Therapeutics Inc (KROS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KROS|Keros Therapeutics Inc|Price:9.860|Chg%:-0.350 - TradingKey
Keros Therapeutics Inc (KROS) Cash Flow - TradingKey
Keros Therapeutics, Inc. Revenue Breakdown – NASDAQ:KROS - TradingView
Keros Therapeutics Inc (KROS) Institutional Confidence - TradingKey
Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
KROS|Keros Therapeutics Inc|Price:10.060|Chg%:-0.080 - TradingKey
Keros TherapeuticsKeith Regnante Resigns As CFO - TradingView
Keros Therapeutics Announces CFO Resignation and Interim Successor - TipRanks
Keros Therapeutics (NASDAQ: KROS) names interim finance and accounting head - Stock Titan
Discipline and Rules-Based Execution in KROS Response - Stock Traders Daily
Keros Therapeutics CFO Keith Regnante resigns effective Aug. 3 - scanx.trade
Keros Therapeutics (KROS) Holds Steady Near Support LevelUp Down Volume - dars.gov.et
Keros Therapeutics (KROS) director adds 1,000 shares under 10b5-1 plan - Stock Titan
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):